Pharmacy World and Science

, Volume 28, Issue 3, pp 123–125 | Cite as

Bacterial meningitis associated with infliximab

  • Raymond FarahEmail author
  • Svetlana Lisitsin
  • Moshe Shay


We report an episode of bacterial meningitis in a 45 year-old woman, who was treated with infliximab for Wegener’s granulomatosis. This patient presented with the classic clinical presentation of acute meningitis: the triad of fever, neck stiffness, and an altered mental state that appeared 6 months after the infliximab initiation. A computed tomographic (CT) scan of the head showed cerebral edema and Streptococcus peumoniae was isolated from blood and CSF cultures. Prompt diagnosis and early treatment improved the outcome of this patient.


Infliximab Meningitis TNF-α Wegener’s granulomatosis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.



We thank Ms Tobie Kuritsky for grammatical correction of the article.


  1. 1.
    Bang LM, Keating GM. Adalimumab: a review of its use in rheumatoid arthritis. BioDrugs 2004;18(2):121–39CrossRefPubMedGoogle Scholar
  2. 2.
    Tak PP. Effects of infliximab treatment on rheumatoid synovial tissue. J Rheumatol Suppl 2005 Mar;74:31–4PubMedGoogle Scholar
  3. 3.
    Van der Heijde D, Dijkmans B, et al. Ankylosing spondylitis study for the evaluation of recombinant infliximab therapy study group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005 Feb;52(2):582–91CrossRefPubMedGoogle Scholar
  4. 4.
    Sandborn WJ. New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease. Rev Gastroenterol Disord 2005 Winter;5(1):10–8PubMedGoogle Scholar
  5. 5.
    Kleinert J, Lorenz M, Kostler W, et al. Refractory Wegener’s granulomatosis responds to tumor necrosis factor blockade. Wien Klin Wochenschr 2004 May 31;116(9–10):334–8CrossRefPubMedGoogle Scholar
  6. 6.
    Hellmich B, Lamprecht P, Gross WL. Advances in the therapy of Wegener’s granulomatosis. Curr Opin Rheumatol 2006 Jan;18(1):25–32CrossRefPubMedGoogle Scholar
  7. 7.
    Allanore Y, Sellam J, Batteux F, et al. Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab. Clin Exp Rheumatol 2004 Nov–Dec;22(6):756–8PubMedGoogle Scholar
  8. 8.
    Hegde N, Gayomali C, Rich MW. Infliximab-induced headache and infliximab-induced meningitis: two ends of the same spectrum? South Med J 2005 May;98(5):564–6CrossRefPubMedGoogle Scholar
  9. 9.
    Bowie VL, Snella KA, Gopalachar AS, Bharadwaj P. Listeria meningitis associated with infliximab. Ann Pharmacother 2004 Jan;38(1):58–61CrossRefPubMedGoogle Scholar
  10. 10.
    Kashyap AS, Kashyap S. Infliximab-induced aseptic meningitis. Lancet 2002 Apr 6;359(9313):1252CrossRefPubMedGoogle Scholar
  11. 11.
    Batsis JA, Phy MP. West Nile virus meningitis in a chronic immunosuppressed patient with rheumatoid arthritis. Clin Rheumatol 2005 Sep;24(5):548–50. Epub 2005 Apr 23CrossRefPubMedGoogle Scholar
  12. 12.
    Marotte H, Charrin JE, Miossec P. Infliximab-induced aseptic meningitis. Lancet 2001 Nov 24;358(9295):1784CrossRefPubMedGoogle Scholar
  13. 13.
    Dayer JM, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985 Dec 1;162(6):2163–8CrossRefPubMedGoogle Scholar
  14. 14.
    Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986 Aug 7–13;322(6079):547–9CrossRefPubMedGoogle Scholar
  15. 15.
    Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001 Oct 11;345(15):1098–104CrossRefPubMedGoogle Scholar
  16. 16.
    Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981 Aug;30(2):239–45PubMedCrossRefGoogle Scholar
  17. 17.
    Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents, specifically tumour necrosis factor-α (TNF-α) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Ann Rheum Dis 2004 Nov;63(Suppl. 2):ii2–ii12CrossRefPubMedGoogle Scholar
  18. 18.
    Hyrich KL, Silman AJ, Watson KD, Symmons DP. Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis 2004 Dec;63(12):1538–43CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2006

Authors and Affiliations

  1. 1.Department of Internal Medicine F-Nahariya Hospital, B. Rappaport Faculty of MedicineWestern Galilee HospitalTechnion, NahariyaIsrael

Personalised recommendations